围手术期使用双吡酮(安乃近)的建议:德国疼痛学会急性疼痛工作组、德国麻醉与重症医学学会疼痛医学科学工作组及德国外科学会急性疼痛外科工作组的专家推荐,德国医学会药物委员会代表参与
由于缺乏已发表研究的证据,专家小组通过正式结构化共识流程制定了围手术期双吡酮(安乃近)使用建议,并经相关医学会批准。小组同意短期围手术期使用无需常规血细胞计数,除非患者有中性粒细胞减少风险;医务人员应知晓粒细胞缺乏症的症状与处理;应告知患者风险获益及替代方案。专家组认为双吡酮相较于其他非阿片类镇痛药具有相对良好的风险获益比,并强烈建议对用药数日或出院后继续治疗者进行粒细胞缺乏症症状教育。
要点
- 短期围手术期使用双吡酮不将血细胞计数作为标准,除非患者有中性粒细胞减少风险。
- 强烈推荐对接受双吡酮数日或出院后继续治疗的患者进行粒细胞缺乏症症状教育,因粒细胞缺乏症可在停药后数日发生。
- 医务人员应知晓粒细胞缺乏症的症状及疑似时的处理流程。
- 应告知患者双吡酮的风险与获益及潜在替代方案。
- 专家组认为双吡酮相较于其他非阿片类镇痛药具有相对良好的风险获益比。
适用人群与场景
- 围手术期需要疼痛管理的患者,具体适用人群与排除人群原文未详细列出。
处置流程与药物剂量
- 短期围手术期使用双吡酮时,不将血细胞计数作为标准,除非患者有中性粒细胞减少风险。
- 医务人员应知晓粒细胞缺乏症的症状及疑似时的处理流程。
- 应告知患者双吡酮的风险与获益及潜在替代方案。
- 强烈建议对已接受双吡酮数日或出院后继续治疗的患者进行粒细胞缺乏症症状教育。
- 出院后需告知接管患者治疗的医生相关信息。
- 对既往发生双吡酮诱导的粒细胞缺乏症的患者,避免再次暴露。
研究设计与关键结果
- 专家小组通过正式结构化共识流程制定建议,并经相关医学会批准。
- 专家组认为双吡酮相较于其他非阿片类镇痛药具有相对良好的风险获益比。
证据类型、等级与局限
- 证据类型:专家推荐(共识)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 短期围手术期使用双吡酮不常规查血常规,除非有中性粒细胞减少风险。
- 对用药数日或出院后继续治疗者,应教育粒细胞缺乏症症状(强烈推荐)。
- 医务人员应知晓粒细胞缺乏症症状及处理流程。
- 告知患者风险获益及替代方案。
- 出院后告知接管医生,既往双吡酮诱导粒细胞缺乏症者避免再次暴露。
指南或共识出处
- 德国疼痛学会急性疼痛工作组、德国麻醉与重症医学学会疼痛医学科学工作组、德国外科学会急性疼痛外科工作组的专家推荐,德国医学会药物委员会代表参与。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Dipyrone (metamizole) is widely used for perioperative pain management in countries where it is marketed; however, uncertainty exists concerning the safe use of this drug, specifically considering the rare adverse event of an agranulocytosis.
METHODS: As evidence from published studies was lacking, an expert panel developed recommendations for the perioperative use of dipyrone. After a formal, structured consensus process, the recommendations were approved by the involved medical societies.
RESULTS: The panel agreed that blood cell counts shall not be standard for short-term perioperative use in patients unless they are at risk for neutropenia. The medical staff shall be aware of the symptoms and course of action when agranulocytosis is suspected. Patients shall be informed about the risks and benefits of dipyrone and about potential alternatives. The expert group concluded that dipyrone has a relatively positive risk-benefit ratio compared to other nonopioid analgesics. The group strongly recommended educating patients about the symptoms of agranulocytosis if they have received dipyrone over several days and/or treatment is to be continued after discharge, because agranulocytosis can occur several days after discontinuation of metamizole. Further recommendations refer to the information of the physician taking over the patient's care after discharge and the avoidance of re-exposure in patients having previously suffered from dipyrone-induced agranulocytosis.
CONCLUSION: The group's recommendations shall be communicated in order to raise medical staff's and patients' awareness of the appropriate use of dipyrone in the perioperative period.
参考来源
- Stamer UM, Stammschulte T, Erlenwein J, et al. [Recommendations for the perioperative use of dipyrone : Expert recommendation of the working group on acute pain of the German Pain Society, the scientific working group on pain medicine of the German Society for Anesthesiology and Intensive Care Medicine and the surgical working group on acute pain of the German Society for Surgery with participation of representatives of the Drug Commission of the German Medical Association]. Chirurg. 2019. PMID: 31359112. doi:10.1007/s00104-019-0993-2
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。